Oncology Nurse Advisor has partnered with leading medical publishers to present Publishers Alliance, a selection of oncology-focused articles from a number of clinically relevant research journals.
Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway
[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.
[OncoTargets and Therapy] In a review of cancer stem cells (CSCs)/ovarian cancer stem cells (OCSCs), researchers discuss the implications of immunotherapy development based on studying cancer evolution by CSCs, and targeting OCSC surface markers to develop CAR-T immunotherapy.
Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden
[Lung Cancer: Targets and Therapy] This case study demonstrates that genomic profiling may still benefit patients who fail checkpoint inhibitor therapy despite having high tumor mutational burden and PD-L1 positivity.
Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer
[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.
[Lung Cancer: Targets and Therapy] Italian researchers report on the role of GLI1 in the development of lung cancer, and review its potential as an effective therapy for lung cancer.
[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.
[Gastrointestinal Cancer: Targets and Therapy] This review presents the most up-to-date molecular, clinical, and therapeutic data, including an overview of a current phase 3 study assessing the efficacy of simultaneous BRAF, EGFR, and MEK inhibition among patients with BRAFV600E-mutant CRC.
Clinicopathological Features and Prognosis in Elderly Gastric Cancer Patients: A Retrospective Cohort Study
[OncoTargets and Therapy] A retrospective study assessed patients with gastric cancer, identifying disease characteristics more prevalent in elderly patients and the effect on prognosis for these patients.
[Breast Cancer: Targets and Therapy] Researchers present a review of the LHRH agonist triptorelin and the use of this agent to induce chemical castration in estrogen-sensitive breast cancer tumors in younger women.
Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?
[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.
Our Publishing Partners
ARE YOU A PUBLISHER LOOKING TO JOIN OUR PUBLISHERS ALLIANCE TEAM? FIND OUT MORE!
Your research articles may be of interest
CLICK HERE to e-mail the Editor for more information!
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|